Recent Submissions

  • An inhibitor of oxidative phosphorylation exploits cancer vulnerability. 

    Molina, Jennifer R; Sun, Yuting; Protopopova, Marina; Gera, Sonal; Bandi, Madhavi; Bristow, Christopher; McAfoos, Timothy et al. (Springer Nature, 2018-06-11)
    Metabolic reprograming is an emerging hallmark of tumor biology and an actively pursued opportunity in oncology drug discovery. Extensive efforts have focused on therapeutic targeting of glycolysis, whereas drugging ...
  • SURF1 knockout cloned pigs: Early onset of a severe lethal phenotype. 

    Quadalti, C; Brunetti, D; Lagutina, I; Duchi, R; Perota, A; Lazzari, G; Cerutti, R et al. (Elsevier, 2018-06)
    Leigh syndrome (LS) associated with cytochrome c oxidase (COX) deficiency is an early onset, fatal mitochondrial encephalopathy, leading to multiple neurological failure and eventually death, usually in the first decade ...
  • Lifelong Reduction in Complex IV Induces Tissue Specific Metabolic Effects But Does Not Reduce Lifespan or Healthspan in Mice 

    Viscomi, Carlo Fiore (Wiley-Blackwell, 2018-04-25)
    Loss of SURF1, a Complex IV assembly protein, was reported to increase lifespan in mice despite dramatically lower cytochrome oxidase (COX) activity. Consistent with this, our previous studies found advantageous changes ...
  • Treating the placenta to prevent adverse effects of gestational hypoxia on fetal brain development. 

    Phillips, Tom J; Scott, Hannah; Menassa, David A; Bignell, Ashleigh L; Sood, Aman; Morton, Jude S; Akagi, Takami et al. (2017-08-22)

View more